Why the study?
Does low body weight (< 60 kg) increase the risk of adverse clinical outcomes in patients with acute coronary syndrome?
Does low body weight (< 60 kg) increase the risk of adverse clinical outcomes in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
In patients with acute coronary syndrome, low body weight (< 60 kg) is associated with a significantly higher risk of MACE and mortality at 12 months compared to non-low body weight, without an increase in bleeding events.
BACKGROUND: inhibitors. AIMS: We aimed to examine differences in mortality, catheterizations/revascularizations, antiplatelet therapy and ischemic/bleeding adverse events between ACS patients with LBW. METHODS: This is a multicenter registry involving 1576 consecutive ACS patients (ST-elevation myocardial infarction (STEMI), non-STEMI, or unstable angina) from three tertiary institutions. Patients were divided into two groups: LBW (weight < 60 kg, n = 176) and non-LBW (weight ⩾ 60 kg, n = 1400). During 12 months follow-up, we recorded management (catheterizations/revascularizations), antiplatelet therapy, major adverse cardiovascular events (MACEs), bleeding events (BARC classification), and mortality. RESULTS: inhibitors was also lower in LBW patients (24.4% vs. 37.8%; p = 0.001). After 12-month follow-up, the incidence of MACE (HR 1.61 (95% CI 1.03-2.50]; p = 0.038) and mortality (HR 2.18 (95% CI 1.33-3.58); p = 0.002) was higher in LBW patients compared with non-LBW. In contrast, there were no significant differences for bleeding events. CONCLUSIONS: inhibitors were less prescribed in LBW patients.
No takes yet. Share an insight, caveat, or question.
Rivera‐Caravaca et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: